← Back to patent-cliff list
GAL-101
Tier C — Watch / tradeGAL-101
Tel Aviv University Trust
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：APP
Indications (approved)：Alzheimer's disease, 地图状萎缩, Glaucoma
Regional status
US
Phase II
2024-06-01
EU
Phase II
2025-01-10
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of GAL-101?
Approved indications include: Alzheimer's disease, 地图状萎缩, Glaucoma.
When does the GAL-101 patent expire?
No public expiry year is available for GAL-101 yet; this page updates once verified.
How do I get a quote for GAL-101 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01